Premium
Intravenous morphine and nalbuphine increase histamine and catecholamine release without accompanying hemodynamic changes
Author(s) -
Doenicke Alfred,
Moss Jonathan,
Lorenz Wilfried,
Hoernecke Rainer
Publication year - 1995
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/0009-9236(95)90075-6
Subject(s) - nalbuphine , histamine , morphine , medicine , anesthesia , opiate , hemodynamics , catecholamine , pharmacology , opioid , receptor
Patients receiving intravenous morphine at doses of 0.3 and 1.0 mg/kg for general anesthesia have been reported to show significant elevations in plasma histamine that are associated with hemodynamic changes. We undertook a prospective, randomized, double‐blind trial in which 0.15 mg/kg morphine or 0.3 mg/kg nalbuphine was administered intravenously to normal volunteers. Thirteen of 15 subjects receiving morphine and 10 of 14 subjects receiving nalbuphine had elevations in plasma histamine levels and symptoms of histamine release within 5 minutes of drug administration. Six subjects in the morphine group and five in the nalbuphine group exhibited levels of plasma histamine >2.0 ng/ml, but these levels were not associated with hemodynamic changes and occurred 10 to 15 minutes after drug administration. Our study suggests that the opiate‐induced elevation of plasma histamine derives from cutaneous mast cells. Clinical Pharmacology & Therapeutics (1995) 58 , 81–89; doi: 10.1016/0009‐9236(95)90075‐6